Intellectual property

The patent application for TL-532 and a new family of TLR3 ligands was filed by TOLLYS in 2018 (EP 18305561).

Toll_like_receptor_3 Tollys
Logo Tollys

Tollys

Triggering & installing efficient anti-tumor immunity

Office

60 avenue Rockefeller
69008 Lyon, FRANCE

Contact us